摘要
目的 :观察国产降纤酶治疗急性脑梗塞的临床疗效及生化指标变化 ,并与日产东菱精纯克栓酶、脉络宁进行比较。方法 :选择 90例急性脑梗塞病人 ,随机分成A组 (降纤酶 )、B组 (东菱精纯克栓酶 )、C组 (脉络宁 )。结果 :A组临床总有效率和显效率分别为 97%和 80 % ,B组分别为 97%和 83% ,两组疗效经Ridit分析差异无显著性 ,各项指标相接近 ,A、B两组均明显优于C组。结论 :降纤酶与东菱精纯克栓酶一样是治疗急性脑梗塞的有效药物 ,且副作用小 。
objectives: To observe the efficacy and the changes of its biochemical criterion in treatment of acute cere br al infarctions with nation made Defibrase, and to compare Defibrase with Japan-m ade Batroxobin and Mai Luo Ning. Methods: 90 cases of acute cerebral infarctions were divided into 3 groups at random,Grou p A (with Def ibrase),Group B (with Batroxobin) and group C (with Mai Luo Ning). Results: The total rate of effect and that of effectiveness of group A were 97% and80% respectively, 97%and 83 % with group B, No obvious difference was an alyzed by Ridit between the two groups in effect,and the criterions were simila r,The clinical effect of group A and B was remarkably better than group C. Conclusion:Like Batroobin,Defibrase was an effect ive drug for acute cerebral infarctions,with less side effects and in low price.
出处
《中国民政医学杂志》
2001年第5期262-263,313,共3页
Medical Journal of Chinese Civil Administration
